nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—LRRK2—Parkinson's disease	0.642	1	CbGaD
Ruxolitinib—HIPK2—brainstem—Parkinson's disease	0.000762	0.00516	CbGeAlD
Ruxolitinib—TAOK3—hindbrain—Parkinson's disease	0.000752	0.0051	CbGeAlD
Ruxolitinib—GRK1—head—Parkinson's disease	0.000749	0.00508	CbGeAlD
Ruxolitinib—PRKG2—nervous system—Parkinson's disease	0.000744	0.00504	CbGeAlD
Ruxolitinib—HIPK2—forebrain—Parkinson's disease	0.000735	0.00498	CbGeAlD
Ruxolitinib—PRKCE—head—Parkinson's disease	0.000733	0.00497	CbGeAlD
Ruxolitinib—PRKG2—central nervous system—Parkinson's disease	0.000716	0.00486	CbGeAlD
Ruxolitinib—GRK1—nervous system—Parkinson's disease	0.00071	0.00481	CbGeAlD
Ruxolitinib—PLK1—head—Parkinson's disease	0.000704	0.00477	CbGeAlD
Ruxolitinib—RPS6KA6—head—Parkinson's disease	0.000704	0.00477	CbGeAlD
Ruxolitinib—MAST1—head—Parkinson's disease	0.000704	0.00477	CbGeAlD
Ruxolitinib—PRKCE—nervous system—Parkinson's disease	0.000695	0.00471	CbGeAlD
Ruxolitinib—CAMK1—medulla oblongata—Parkinson's disease	0.000693	0.0047	CbGeAlD
Ruxolitinib—DYRK1A—brainstem—Parkinson's disease	0.000685	0.00464	CbGeAlD
Ruxolitinib—GRK1—central nervous system—Parkinson's disease	0.000683	0.00463	CbGeAlD
Ruxolitinib—BMPR2—brainstem—Parkinson's disease	0.000682	0.00463	CbGeAlD
Ruxolitinib—ROCK1—forebrain—Parkinson's disease	0.000678	0.0046	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—Parkinson's disease	0.000669	0.00453	CbGeAlD
Ruxolitinib—RPS6KA6—nervous system—Parkinson's disease	0.000667	0.00452	CbGeAlD
Ruxolitinib—PLK1—nervous system—Parkinson's disease	0.000667	0.00452	CbGeAlD
Ruxolitinib—MAST1—nervous system—Parkinson's disease	0.000667	0.00452	CbGeAlD
Ruxolitinib—DCLK3—head—Parkinson's disease	0.000667	0.00452	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—Parkinson's disease	0.000666	0.00451	CbGeAlD
Ruxolitinib—DYRK1A—forebrain—Parkinson's disease	0.000661	0.00448	CbGeAlD
Ruxolitinib—BMPR2—forebrain—Parkinson's disease	0.000659	0.00446	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—Parkinson's disease	0.000654	0.00443	CbGeAlD
Ruxolitinib—PLK1—central nervous system—Parkinson's disease	0.000643	0.00436	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—Parkinson's disease	0.000643	0.00436	CbGeAlD
Ruxolitinib—MAST1—central nervous system—Parkinson's disease	0.000643	0.00436	CbGeAlD
Ruxolitinib—DCLK3—nervous system—Parkinson's disease	0.000633	0.00429	CbGeAlD
Ruxolitinib—RPS6KA6—cerebellum—Parkinson's disease	0.000628	0.00426	CbGeAlD
Ruxolitinib—MAST1—cerebellum—Parkinson's disease	0.000628	0.00426	CbGeAlD
Ruxolitinib—HIPK2—cardiovascular system—Parkinson's disease	0.000621	0.00421	CbGeAlD
Ruxolitinib—CAMK1—spinal cord—Parkinson's disease	0.000618	0.00419	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—Parkinson's disease	0.000611	0.00414	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—Parkinson's disease	0.000609	0.00413	CbGeAlD
Ruxolitinib—LRRK2—brainstem—Parkinson's disease	0.000605	0.0041	CbGeAlD
Ruxolitinib—DAPK3—cardiovascular system—Parkinson's disease	0.000597	0.00405	CbGeAlD
Ruxolitinib—BMP2K—forebrain—Parkinson's disease	0.000589	0.004	CbGeAlD
Ruxolitinib—CAMK2G—forebrain—Parkinson's disease	0.000589	0.004	CbGeAlD
Ruxolitinib—PLK3—head—Parkinson's disease	0.000588	0.00398	CbGeAlD
Ruxolitinib—LRRK2—forebrain—Parkinson's disease	0.000584	0.00396	CbGeAlD
Ruxolitinib—ROCK1—cardiovascular system—Parkinson's disease	0.000573	0.00389	CbGeAlD
Ruxolitinib—JAK1—medulla oblongata—Parkinson's disease	0.000569	0.00386	CbGeAlD
Ruxolitinib—DCLK1—medulla oblongata—Parkinson's disease	0.000569	0.00386	CbGeAlD
Ruxolitinib—PRKG2—brain—Parkinson's disease	0.000569	0.00386	CbGeAlD
Ruxolitinib—LTK—head—Parkinson's disease	0.000567	0.00385	CbGeAlD
Ruxolitinib—RET—embryo—Parkinson's disease	0.000567	0.00384	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—Parkinson's disease	0.000559	0.00379	CbGeAlD
Ruxolitinib—PLK3—nervous system—Parkinson's disease	0.000557	0.00378	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—Parkinson's disease	0.000557	0.00378	CbGeAlD
Ruxolitinib—CAMK1D—medulla oblongata—Parkinson's disease	0.000555	0.00376	CbGeAlD
Ruxolitinib—PHKG2—medulla oblongata—Parkinson's disease	0.000552	0.00374	CbGeAlD
Ruxolitinib—CAMK1—head—Parkinson's disease	0.00055	0.00373	CbGeAlD
Ruxolitinib—DAPK2—medulla oblongata—Parkinson's disease	0.000543	0.00368	CbGeAlD
Ruxolitinib—GRK1—brain—Parkinson's disease	0.000543	0.00368	CbGeAlD
Ruxolitinib—PLK3—central nervous system—Parkinson's disease	0.000536	0.00364	CbGeAlD
Ruxolitinib—JAK2—embryo—Parkinson's disease	0.000535	0.00363	CbGeAlD
Ruxolitinib—MARK2—head—Parkinson's disease	0.000534	0.00362	CbGeAlD
Ruxolitinib—PRKCE—brain—Parkinson's disease	0.000531	0.0036	CbGeAlD
Ruxolitinib—CAMK1—nervous system—Parkinson's disease	0.000521	0.00353	CbGeAlD
Ruxolitinib—JAK1—midbrain—Parkinson's disease	0.00052	0.00352	CbGeAlD
Ruxolitinib—DCLK1—midbrain—Parkinson's disease	0.00052	0.00352	CbGeAlD
Ruxolitinib—DAPK3—medulla oblongata—Parkinson's disease	0.00051	0.00346	CbGeAlD
Ruxolitinib—RPS6KA6—brain—Parkinson's disease	0.00051	0.00346	CbGeAlD
Ruxolitinib—PLK1—brain—Parkinson's disease	0.00051	0.00346	CbGeAlD
Ruxolitinib—MAST1—brain—Parkinson's disease	0.00051	0.00346	CbGeAlD
Ruxolitinib—JAK1—spinal cord—Parkinson's disease	0.000507	0.00344	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—Parkinson's disease	0.000507	0.00344	CbGeAlD
Ruxolitinib—MARK2—nervous system—Parkinson's disease	0.000506	0.00343	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—Parkinson's disease	0.000502	0.0034	CbGeAlD
Ruxolitinib—CAMK2G—cardiovascular system—Parkinson's disease	0.000498	0.00338	CbGeAlD
Ruxolitinib—DAPK2—midbrain—Parkinson's disease	0.000496	0.00336	CbGeAlD
Ruxolitinib—CAMK1—cerebellum—Parkinson's disease	0.00049	0.00332	CbGeAlD
Ruxolitinib—MARK2—central nervous system—Parkinson's disease	0.000487	0.0033	CbGeAlD
Ruxolitinib—DAPK2—spinal cord—Parkinson's disease	0.000484	0.00328	CbGeAlD
Ruxolitinib—DCLK3—brain—Parkinson's disease	0.000484	0.00328	CbGeAlD
Ruxolitinib—MARK2—cerebellum—Parkinson's disease	0.000476	0.00323	CbGeAlD
Ruxolitinib—BMPR2—medulla oblongata—Parkinson's disease	0.000476	0.00323	CbGeAlD
Ruxolitinib—JAK2—forebrain—Parkinson's disease	0.000474	0.00321	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—Parkinson's disease	0.000474	0.00321	CbGeAlD
Ruxolitinib—DAPK3—midbrain—Parkinson's disease	0.000466	0.00316	CbGeAlD
Ruxolitinib—DAPK3—spinal cord—Parkinson's disease	0.000455	0.00308	CbGeAlD
Ruxolitinib—JAK3—head—Parkinson's disease	0.000454	0.00308	CbGeAlD
Ruxolitinib—JAK1—head—Parkinson's disease	0.000451	0.00306	CbGeAlD
Ruxolitinib—DCLK1—head—Parkinson's disease	0.000451	0.00306	CbGeAlD
Ruxolitinib—TAOK2—cerebellum—Parkinson's disease	0.00044	0.00299	CbGeAlD
Ruxolitinib—TYK2—cardiovascular system—Parkinson's disease	0.00044	0.00298	CbGeAlD
Ruxolitinib—CAMK1D—head—Parkinson's disease	0.00044	0.00298	CbGeAlD
Ruxolitinib—PHKG2—head—Parkinson's disease	0.000437	0.00297	CbGeAlD
Ruxolitinib—BMPR2—midbrain—Parkinson's disease	0.000435	0.00295	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—Parkinson's disease	0.000434	0.00295	CbGeAlD
Ruxolitinib—TAOK3—brainstem—Parkinson's disease	0.000431	0.00292	CbGeAlD
Ruxolitinib—JAK3—nervous system—Parkinson's disease	0.00043	0.00292	CbGeAlD
Ruxolitinib—JAK1—nervous system—Parkinson's disease	0.000427	0.0029	CbGeAlD
Ruxolitinib—DCLK1—nervous system—Parkinson's disease	0.000427	0.0029	CbGeAlD
Ruxolitinib—CAMK2G—medulla oblongata—Parkinson's disease	0.000426	0.00289	CbGeAlD
Ruxolitinib—PLK3—brain—Parkinson's disease	0.000426	0.00289	CbGeAlD
Ruxolitinib—STK16—head—Parkinson's disease	0.000423	0.00287	CbGeAlD
Ruxolitinib—LRRK2—medulla oblongata—Parkinson's disease	0.000422	0.00286	CbGeAlD
Ruxolitinib—HIPK2—head—Parkinson's disease	0.000421	0.00285	CbGeAlD
Ruxolitinib—CAMK1D—nervous system—Parkinson's disease	0.000417	0.00283	CbGeAlD
Ruxolitinib—TAOK3—forebrain—Parkinson's disease	0.000416	0.00282	CbGeAlD
Ruxolitinib—PHKG2—nervous system—Parkinson's disease	0.000415	0.00281	CbGeAlD
Ruxolitinib—JAK3—central nervous system—Parkinson's disease	0.000414	0.00281	CbGeAlD
Ruxolitinib—MAP3K19—head—Parkinson's disease	0.000412	0.0028	CbGeAlD
Ruxolitinib—JAK1—central nervous system—Parkinson's disease	0.000411	0.00279	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—Parkinson's disease	0.000411	0.00279	CbGeAlD
Ruxolitinib—LTK—brain—Parkinson's disease	0.000411	0.00279	CbGeAlD
Ruxolitinib—JAK3—cerebellum—Parkinson's disease	0.000405	0.00274	CbGeAlD
Ruxolitinib—DAPK3—head—Parkinson's disease	0.000404	0.00274	CbGeAlD
Ruxolitinib—JAK1—cerebellum—Parkinson's disease	0.000402	0.00273	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—Parkinson's disease	0.000402	0.00273	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—Parkinson's disease	0.000402	0.00272	CbGeAlD
Ruxolitinib—STK16—nervous system—Parkinson's disease	0.000401	0.00272	CbGeAlD
Ruxolitinib—CLK2—head—Parkinson's disease	0.000401	0.00272	CbGeAlD
Ruxolitinib—JAK2—cardiovascular system—Parkinson's disease	0.0004	0.00271	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—Parkinson's disease	0.000399	0.00271	CbGeAlD
Ruxolitinib—HIPK2—nervous system—Parkinson's disease	0.000399	0.0027	CbGeAlD
Ruxolitinib—CAMK1—brain—Parkinson's disease	0.000398	0.0027	CbGeAlD
Ruxolitinib—CAMK1D—cerebellum—Parkinson's disease	0.000393	0.00266	CbGeAlD
Ruxolitinib—MAP3K19—nervous system—Parkinson's disease	0.000391	0.00265	CbGeAlD
Ruxolitinib—PHKG2—cerebellum—Parkinson's disease	0.00039	0.00265	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—Parkinson's disease	0.000389	0.00264	CbGeAlD
Ruxolitinib—BMP2K—midbrain—Parkinson's disease	0.000389	0.00264	CbGeAlD
Ruxolitinib—ROCK1—head—Parkinson's disease	0.000388	0.00263	CbGeAlD
Ruxolitinib—MARK2—brain—Parkinson's disease	0.000387	0.00262	CbGeAlD
Ruxolitinib—STK16—central nervous system—Parkinson's disease	0.000386	0.00262	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—Parkinson's disease	0.000386	0.00262	CbGeAlD
Ruxolitinib—LRRK2—midbrain—Parkinson's disease	0.000386	0.00261	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—Parkinson's disease	0.000384	0.0026	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—Parkinson's disease	0.000384	0.0026	CbGeAlD
Ruxolitinib—DAPK3—nervous system—Parkinson's disease	0.000383	0.0026	CbGeAlD
Ruxolitinib—MAP3K7—medulla oblongata—Parkinson's disease	0.000383	0.0026	CbGeAlD
Ruxolitinib—CLK2—nervous system—Parkinson's disease	0.00038	0.00257	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—Parkinson's disease	0.00038	0.00257	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—Parkinson's disease	0.00038	0.00257	CbGeAlD
Ruxolitinib—DYRK1A—head—Parkinson's disease	0.000379	0.00257	CbGeAlD
Ruxolitinib—STK16—cerebellum—Parkinson's disease	0.000377	0.00256	CbGeAlD
Ruxolitinib—BMPR2—head—Parkinson's disease	0.000377	0.00256	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—Parkinson's disease	0.000376	0.00255	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—Parkinson's disease	0.000376	0.00255	CbGeAlD
Ruxolitinib—TYK2—medulla oblongata—Parkinson's disease	0.000376	0.00255	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—Parkinson's disease	0.000375	0.00255	CbGeAlD
Ruxolitinib—MKNK2—medulla oblongata—Parkinson's disease	0.000371	0.00252	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—Parkinson's disease	0.000369	0.0025	CbGeAlD
Ruxolitinib—ROCK1—nervous system—Parkinson's disease	0.000368	0.0025	CbGeAlD
Ruxolitinib—CLK2—central nervous system—Parkinson's disease	0.000366	0.00248	CbGeAlD
Ruxolitinib—RET—medulla oblongata—Parkinson's disease	0.000362	0.00245	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—Parkinson's disease	0.000361	0.00245	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—Parkinson's disease	0.000359	0.00243	CbGeAlD
Ruxolitinib—TAOK2—brain—Parkinson's disease	0.000358	0.00243	CbGeAlD
Ruxolitinib—BMPR2—nervous system—Parkinson's disease	0.000358	0.00242	CbGeAlD
Ruxolitinib—CLK2—cerebellum—Parkinson's disease	0.000357	0.00242	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—Parkinson's disease	0.000354	0.0024	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—Parkinson's disease	0.000352	0.00239	CbGeAlD
Ruxolitinib—MAP3K7—midbrain—Parkinson's disease	0.00035	0.00237	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—Parkinson's disease	0.000346	0.00234	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—Parkinson's disease	0.000344	0.00233	CbGeAlD
Ruxolitinib—TYK2—midbrain—Parkinson's disease	0.000344	0.00233	CbGeAlD
Ruxolitinib—JAK2—medulla oblongata—Parkinson's disease	0.000342	0.00232	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—Parkinson's disease	0.000342	0.00232	CbGeAlD
Ruxolitinib—MKNK2—midbrain—Parkinson's disease	0.000339	0.0023	CbGeAlD
Ruxolitinib—IRAK1—midbrain—Parkinson's disease	0.000339	0.0023	CbGeAlD
Ruxolitinib—DYRK1A—cerebellum—Parkinson's disease	0.000338	0.00229	CbGeAlD
Ruxolitinib—BMP2K—head—Parkinson's disease	0.000337	0.00229	CbGeAlD
Ruxolitinib—CAMK2G—head—Parkinson's disease	0.000337	0.00229	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—Parkinson's disease	0.000336	0.00228	CbGeAlD
Ruxolitinib—TYK2—spinal cord—Parkinson's disease	0.000335	0.00227	CbGeAlD
Ruxolitinib—LRRK2—head—Parkinson's disease	0.000334	0.00227	CbGeAlD
Ruxolitinib—MKNK2—spinal cord—Parkinson's disease	0.000331	0.00224	CbGeAlD
Ruxolitinib—RET—midbrain—Parkinson's disease	0.000331	0.00224	CbGeAlD
Ruxolitinib—MAP3K3—medulla oblongata—Parkinson's disease	0.00033	0.00224	CbGeAlD
Ruxolitinib—JAK3—brain—Parkinson's disease	0.000329	0.00223	CbGeAlD
Ruxolitinib—JAK1—brain—Parkinson's disease	0.000327	0.00221	CbGeAlD
Ruxolitinib—DCLK1—brain—Parkinson's disease	0.000327	0.00221	CbGeAlD
Ruxolitinib—PLK4—brain—Parkinson's disease	0.000325	0.0022	CbGeAlD
Ruxolitinib—RET—spinal cord—Parkinson's disease	0.000323	0.00219	CbGeAlD
Ruxolitinib—NUAK2—cerebellum—Parkinson's disease	0.000322	0.00218	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—Parkinson's disease	0.00032	0.00217	CbGeAlD
Ruxolitinib—BMP2K—nervous system—Parkinson's disease	0.00032	0.00217	CbGeAlD
Ruxolitinib—CAMK1D—brain—Parkinson's disease	0.000319	0.00216	CbGeAlD
Ruxolitinib—LRRK2—nervous system—Parkinson's disease	0.000317	0.00215	CbGeAlD
Ruxolitinib—PHKG2—brain—Parkinson's disease	0.000317	0.00215	CbGeAlD
Ruxolitinib—DAPK2—brain—Parkinson's disease	0.000312	0.00211	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—Parkinson's disease	0.000308	0.00209	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—Parkinson's disease	0.000308	0.00209	CbGeAlD
Ruxolitinib—STK16—brain—Parkinson's disease	0.000307	0.00208	CbGeAlD
Ruxolitinib—MAP3K2—head—Parkinson's disease	0.000306	0.00208	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—Parkinson's disease	0.000305	0.00207	CbGeAlD
Ruxolitinib—JAK2—spinal cord—Parkinson's disease	0.000305	0.00207	CbGeAlD
Ruxolitinib—HIPK2—brain—Parkinson's disease	0.000305	0.00207	CbGeAlD
Ruxolitinib—MAP3K3—midbrain—Parkinson's disease	0.000301	0.00204	CbGeAlD
Ruxolitinib—CAMK2G—cerebellum—Parkinson's disease	0.000301	0.00204	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—Parkinson's disease	0.000301	0.00204	CbGeAlD
Ruxolitinib—TAOK3—medulla oblongata—Parkinson's disease	0.000301	0.00204	CbGeAlD
Ruxolitinib—MAP3K19—brain—Parkinson's disease	0.000299	0.00203	CbGeAlD
Ruxolitinib—LRRK2—cerebellum—Parkinson's disease	0.000298	0.00202	CbGeAlD
Ruxolitinib—TYK2—head—Parkinson's disease	0.000298	0.00202	CbGeAlD
Ruxolitinib—MKNK2—head—Parkinson's disease	0.000294	0.00199	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—Parkinson's disease	0.000294	0.00199	CbGeAlD
Ruxolitinib—DAPK3—brain—Parkinson's disease	0.000293	0.00199	CbGeAlD
Ruxolitinib—MAP3K2—nervous system—Parkinson's disease	0.000291	0.00197	CbGeAlD
Ruxolitinib—CLK2—brain—Parkinson's disease	0.00029	0.00197	CbGeAlD
Ruxolitinib—RET—head—Parkinson's disease	0.000287	0.00195	CbGeAlD
Ruxolitinib—TYK2—nervous system—Parkinson's disease	0.000283	0.00192	CbGeAlD
Ruxolitinib—ROCK1—brain—Parkinson's disease	0.000281	0.00191	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—Parkinson's disease	0.00028	0.0019	CbGeAlD
Ruxolitinib—MKNK2—nervous system—Parkinson's disease	0.000279	0.00189	CbGeAlD
Ruxolitinib—TAOK3—midbrain—Parkinson's disease	0.000275	0.00186	CbGeAlD
Ruxolitinib—DYRK1A—brain—Parkinson's disease	0.000274	0.00186	CbGeAlD
Ruxolitinib—MAP3K2—cerebellum—Parkinson's disease	0.000273	0.00185	CbGeAlD
Ruxolitinib—BMPR2—brain—Parkinson's disease	0.000273	0.00185	CbGeAlD
Ruxolitinib—TYK2—central nervous system—Parkinson's disease	0.000272	0.00184	CbGeAlD
Ruxolitinib—RET—nervous system—Parkinson's disease	0.000272	0.00184	CbGeAlD
Ruxolitinib—JAK2—head—Parkinson's disease	0.000271	0.00184	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—Parkinson's disease	0.000271	0.00184	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—Parkinson's disease	0.000269	0.00182	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—Parkinson's disease	0.000268	0.00182	CbGeAlD
Ruxolitinib—TYK2—cerebellum—Parkinson's disease	0.000266	0.0018	CbGeAlD
Ruxolitinib—MKNK2—cerebellum—Parkinson's disease	0.000262	0.00178	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—Parkinson's disease	0.000262	0.00178	CbGeAlD
Ruxolitinib—RET—central nervous system—Parkinson's disease	0.000262	0.00178	CbGeAlD
Ruxolitinib—MAP3K3—head—Parkinson's disease	0.000261	0.00177	CbGeAlD
Ruxolitinib—NUAK2—brain—Parkinson's disease	0.000261	0.00177	CbGeAlD
Ruxolitinib—JAK2—nervous system—Parkinson's disease	0.000257	0.00174	CbGeAlD
Ruxolitinib—RET—cerebellum—Parkinson's disease	0.000256	0.00174	CbGeAlD
Ruxolitinib—MAP3K3—nervous system—Parkinson's disease	0.000248	0.00168	CbGeAlD
Ruxolitinib—JAK2—central nervous system—Parkinson's disease	0.000248	0.00168	CbGeAlD
Ruxolitinib—CAMK2G—brain—Parkinson's disease	0.000245	0.00166	CbGeAlD
Ruxolitinib—BMP2K—brain—Parkinson's disease	0.000245	0.00166	CbGeAlD
Ruxolitinib—LRRK2—brain—Parkinson's disease	0.000242	0.00164	CbGeAlD
Ruxolitinib—JAK2—cerebellum—Parkinson's disease	0.000242	0.00164	CbGeAlD
Ruxolitinib—MAP3K3—central nervous system—Parkinson's disease	0.000239	0.00162	CbGeAlD
Ruxolitinib—TAOK3—head—Parkinson's disease	0.000238	0.00162	CbGeAlD
Ruxolitinib—MAP3K3—cerebellum—Parkinson's disease	0.000233	0.00158	CbGeAlD
Ruxolitinib—TAOK3—nervous system—Parkinson's disease	0.000226	0.00153	CbGeAlD
Ruxolitinib—MAP3K2—brain—Parkinson's disease	0.000222	0.00151	CbGeAlD
Ruxolitinib—MAP3K7—brain—Parkinson's disease	0.00022	0.00149	CbGeAlD
Ruxolitinib—TAOK3—central nervous system—Parkinson's disease	0.000218	0.00147	CbGeAlD
Ruxolitinib—TYK2—brain—Parkinson's disease	0.000216	0.00146	CbGeAlD
Ruxolitinib—IRAK1—brain—Parkinson's disease	0.000213	0.00145	CbGeAlD
Ruxolitinib—MKNK2—brain—Parkinson's disease	0.000213	0.00145	CbGeAlD
Ruxolitinib—TAOK3—cerebellum—Parkinson's disease	0.000213	0.00144	CbGeAlD
Ruxolitinib—RET—brain—Parkinson's disease	0.000208	0.00141	CbGeAlD
Ruxolitinib—JAK2—brain—Parkinson's disease	0.000197	0.00133	CbGeAlD
Ruxolitinib—MAP3K3—brain—Parkinson's disease	0.000189	0.00128	CbGeAlD
Ruxolitinib—TAOK3—brain—Parkinson's disease	0.000173	0.00117	CbGeAlD
Ruxolitinib—CYP3A4—nervous system—Parkinson's disease	6.86e-05	0.000465	CbGeAlD
Ruxolitinib—CYP3A4—central nervous system—Parkinson's disease	6.61e-05	0.000448	CbGeAlD
Ruxolitinib—JAK2—Signaling by GPCR—DRD2—Parkinson's disease	8.21e-06	3.9e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	8.18e-06	3.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1R—Parkinson's disease	8.17e-06	3.88e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	8.14e-06	3.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—INS—Parkinson's disease	8.11e-06	3.85e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ABL1—Parkinson's disease	8.08e-06	3.84e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HGF—Parkinson's disease	8.07e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EDN1—Parkinson's disease	8.07e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—APOE—Parkinson's disease	8.06e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—IL6—Parkinson's disease	8.06e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—IL6—Parkinson's disease	8.06e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	8.06e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INSR—Parkinson's disease	8.05e-06	3.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—IL6—Parkinson's disease	7.99e-06	3.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—IL6—Parkinson's disease	7.92e-06	3.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—IL6—Parkinson's disease	7.88e-06	3.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GFAP—Parkinson's disease	7.86e-06	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—Parkinson's disease	7.85e-06	3.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGB—Parkinson's disease	7.84e-06	3.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HGF—Parkinson's disease	7.83e-06	3.72e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INSR—Parkinson's disease	7.81e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR1A—Parkinson's disease	7.79e-06	3.7e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—APOE—Parkinson's disease	7.78e-06	3.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GRM5—Parkinson's disease	7.77e-06	3.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ADRBK1—Parkinson's disease	7.75e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MAPK8—Parkinson's disease	7.74e-06	3.67e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—Parkinson's disease	7.72e-06	3.67e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—IL6—Parkinson's disease	7.71e-06	3.66e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TAC1—Parkinson's disease	7.68e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL1B—Parkinson's disease	7.67e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CASP3—Parkinson's disease	7.62e-06	3.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGB—Parkinson's disease	7.61e-06	3.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HGF—Parkinson's disease	7.6e-06	3.61e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL6—Parkinson's disease	7.59e-06	3.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HTR2A—Parkinson's disease	7.59e-06	3.6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	7.59e-06	3.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR1A—Parkinson's disease	7.57e-06	3.59e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD1—Parkinson's disease	7.53e-06	3.57e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	7.48e-06	3.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—IL6—Parkinson's disease	7.46e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TAC1—Parkinson's disease	7.45e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NGF—Parkinson's disease	7.41e-06	3.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGB—Parkinson's disease	7.38e-06	3.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL6—Parkinson's disease	7.37e-06	3.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR1A—Parkinson's disease	7.34e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD1—Parkinson's disease	7.31e-06	3.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD3—Parkinson's disease	7.29e-06	3.46e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF2—Parkinson's disease	7.27e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—IL6—Parkinson's disease	7.24e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—EDN1—Parkinson's disease	7.24e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TAC1—Parkinson's disease	7.23e-06	3.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ADRBK1—Parkinson's disease	7.15e-06	3.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF2—Parkinson's disease	7.15e-06	3.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—Parkinson's disease	7.15e-06	3.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	7.14e-06	3.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HSPA1A—Parkinson's disease	7.1e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD1—Parkinson's disease	7.09e-06	3.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD3—Parkinson's disease	7.08e-06	3.36e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—Parkinson's disease	7.06e-06	3.35e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HTR2A—Parkinson's disease	7.06e-06	3.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MAPK8—Parkinson's disease	7.03e-06	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1R—Parkinson's disease	7.02e-06	3.33e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL1B—Parkinson's disease	7.02e-06	3.33e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MAPK8—Parkinson's disease	7e-06	3.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EDN1—Parkinson's disease	6.94e-06	3.29e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1R—Parkinson's disease	6.91e-06	3.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	6.9e-06	3.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—INS—Parkinson's disease	6.89e-06	3.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD3—Parkinson's disease	6.86e-06	3.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL1B—Parkinson's disease	6.86e-06	3.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EDN1—Parkinson's disease	6.83e-06	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF20—Parkinson's disease	6.82e-06	3.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ADRBK1—Parkinson's disease	6.81e-06	3.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MAPK8—Parkinson's disease	6.66e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—INS—Parkinson's disease	6.64e-06	3.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADORA2A—Parkinson's disease	6.61e-06	3.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ADRBK1—Parkinson's disease	6.61e-06	3.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD2—Parkinson's disease	6.59e-06	3.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR7—Parkinson's disease	6.59e-06	3.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EDN1—Parkinson's disease	6.57e-06	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—APOE—Parkinson's disease	6.56e-06	3.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—Parkinson's disease	6.56e-06	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL1B—Parkinson's disease	6.47e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MAPK8—Parkinson's disease	6.47e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MAPK8—Parkinson's disease	6.44e-06	3.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ADRBK1—Parkinson's disease	6.41e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD2—Parkinson's disease	6.4e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR7—Parkinson's disease	6.4e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTHFR—Parkinson's disease	6.39e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—Parkinson's disease	6.38e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NGF—Parkinson's disease	6.38e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—Parkinson's disease	6.34e-06	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—HTR2A—Parkinson's disease	6.33e-06	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ABL1—Parkinson's disease	6.32e-06	3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MAPK8—Parkinson's disease	6.29e-06	2.99e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MAPK8—Parkinson's disease	6.27e-06	2.98e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NGF—Parkinson's disease	6.27e-06	2.98e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—Parkinson's disease	6.23e-06	2.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR7—Parkinson's disease	6.21e-06	2.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD2—Parkinson's disease	6.21e-06	2.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INSR—Parkinson's disease	6.1e-06	2.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HTR2A—Parkinson's disease	6.07e-06	2.88e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HTR2A—Parkinson's disease	5.97e-06	2.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—APOE—Parkinson's disease	5.95e-06	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HGF—Parkinson's disease	5.94e-06	2.82e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MAPK8—Parkinson's disease	5.93e-06	2.82e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—Parkinson's disease	5.8e-06	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGB—Parkinson's disease	5.76e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HTR2A—Parkinson's disease	5.75e-06	2.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR1A—Parkinson's disease	5.73e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TAC1—Parkinson's disease	5.65e-06	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOE—Parkinson's disease	5.65e-06	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—INS—Parkinson's disease	5.61e-06	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—Parkinson's disease	5.6e-06	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—Parkinson's disease	5.58e-06	2.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL1B—Parkinson's disease	5.57e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOE—Parkinson's disease	5.55e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD1—Parkinson's disease	5.54e-06	2.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF2—Parkinson's disease	5.53e-06	2.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—Parkinson's disease	5.49e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MCCC1—Parkinson's disease	5.38e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ND3—Parkinson's disease	5.38e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD3—Parkinson's disease	5.36e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF2—Parkinson's disease	5.36e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1R—Parkinson's disease	5.34e-06	2.54e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EDN1—Parkinson's disease	5.28e-06	2.51e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—Parkinson's disease	5.26e-06	2.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF2—Parkinson's disease	5.2e-06	2.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1R—Parkinson's disease	5.19e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EDN1—Parkinson's disease	5.12e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MAPK8—Parkinson's disease	5.1e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—INS—Parkinson's disease	5.08e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TALDO1—Parkinson's disease	5.06e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—OMD—Parkinson's disease	5.06e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1R—Parkinson's disease	5.03e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADRBK1—Parkinson's disease	5.01e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EDN1—Parkinson's disease	4.97e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—Parkinson's disease	4.97e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CASP3—Parkinson's disease	4.95e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—Parkinson's disease	4.94e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—Parkinson's disease	4.91e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MAPK8—Parkinson's disease	4.9e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD2—Parkinson's disease	4.85e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NGF—Parkinson's disease	4.85e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR7—Parkinson's disease	4.85e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTHFR—Parkinson's disease	4.84e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—INS—Parkinson's disease	4.82e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	4.79e-06	2.28e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—INS—Parkinson's disease	4.74e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NGF—Parkinson's disease	4.71e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—Parkinson's disease	4.68e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR2A—Parkinson's disease	4.62e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCH1—Parkinson's disease	4.57e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NGF—Parkinson's disease	4.57e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK8—Parkinson's disease	4.55e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—Parkinson's disease	4.51e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—Parkinson's disease	4.49e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR2A—Parkinson's disease	4.48e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—Parkinson's disease	4.47e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—Parkinson's disease	4.39e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR2A—Parkinson's disease	4.35e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—Parkinson's disease	4.29e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—Parkinson's disease	4.26e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL1B—Parkinson's disease	4.23e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CASP3—Parkinson's disease	4.17e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—Parkinson's disease	4.17e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—Parkinson's disease	4.15e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—Parkinson's disease	4.14e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—Parkinson's disease	4.13e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—Parkinson's disease	4.11e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL1B—Parkinson's disease	4.11e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FBP1—Parkinson's disease	4.08e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DBH—Parkinson's disease	4.08e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GBA—Parkinson's disease	4.08e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF2—Parkinson's disease	4.06e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—Parkinson's disease	4.04e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—Parkinson's disease	4.02e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—Parkinson's disease	4.01e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL1B—Parkinson's disease	3.99e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1R—Parkinson's disease	3.93e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EDN1—Parkinson's disease	3.88e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK8—Parkinson's disease	3.88e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—INS—Parkinson's disease	3.85e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK8—Parkinson's disease	3.84e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—Parkinson's disease	3.79e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK8—Parkinson's disease	3.77e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—INS—Parkinson's disease	3.67e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK8—Parkinson's disease	3.65e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—Parkinson's disease	3.59e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NGF—Parkinson's disease	3.57e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—Parkinson's disease	3.57e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INS—Parkinson's disease	3.56e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—Parkinson's disease	3.55e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—Parkinson's disease	3.53e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—Parkinson's disease	3.51e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INS—Parkinson's disease	3.45e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—Parkinson's disease	3.4e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK8—Parkinson's disease	3.3e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—Parkinson's disease	3.26e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK8—Parkinson's disease	3.25e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—Parkinson's disease	3.16e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—Parkinson's disease	3.13e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—Parkinson's disease	3.11e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—Parkinson's disease	3.01e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DDC—Parkinson's disease	2.99e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—Parkinson's disease	2.9e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—Parkinson's disease	2.86e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	2.83e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—Parkinson's disease	2.73e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INS—Parkinson's disease	2.7e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—Parkinson's disease	2.65e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—Parkinson's disease	2.63e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—Parkinson's disease	2.57e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	2.54e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MAOB—Parkinson's disease	2.52e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—Parkinson's disease	2.51e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—Parkinson's disease	2.48e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—Parkinson's disease	2.45e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—Parkinson's disease	2.44e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—Parkinson's disease	2.41e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—Parkinson's disease	2.36e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—Parkinson's disease	2.33e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—Parkinson's disease	2.22e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—Parkinson's disease	2.11e-06	1e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—Parkinson's disease	2.07e-06	9.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—Parkinson's disease	2.01e-06	9.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—Parkinson's disease	2e-06	9.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.87e-06	8.89e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—Parkinson's disease	1.85e-06	8.76e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.84e-06	8.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—Parkinson's disease	1.82e-06	8.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.71e-06	8.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.69e-06	8.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—Parkinson's disease	1.68e-06	7.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TH—Parkinson's disease	1.67e-06	7.92e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—Parkinson's disease	1.6e-06	7.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.6e-06	7.6e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—Parkinson's disease	1.56e-06	7.38e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—Parkinson's disease	1.51e-06	7.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COMT—Parkinson's disease	1.42e-06	6.73e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	1.41e-06	6.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MAOA—Parkinson's disease	1.41e-06	6.69e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	1.39e-06	6.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	1.34e-06	6.34e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	1.3e-06	6.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—Parkinson's disease	1.24e-06	5.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—Parkinson's disease	1.18e-06	5.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	1.15e-06	5.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—Parkinson's disease	1.07e-06	5.07e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—INS—Parkinson's disease	9.12e-07	4.33e-06	CbGpPWpGaD
